Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
2403046 | Vaccine | 2011 | 10 Pages |
Abstract
Dengue. virus infection is the leading arboviral cause of disease worldwide. A vaccine is being developed based on the attenuated DEN-2 virus, DEN-2 PDK-53. In this review, we summarize the characteristics of the parent DEN-2 PDK-53 strain as well as the chimeric viruses containing the prM and E genes of DEN-1, DEN-3 or DEN-4 virus in the genetic backbone of the DEN-2 PDK-53 virus (termed DENVax). Tetravalent DENVax formulations containing cloned, fully sequenced isolates of the DEN-2 PDK-53 virus and the three chimeras have been evaluated for safety and efficacy in preclinical animal models. Based on the safety, immunogenicity and efficacy in preclinical studies, Phase 1 clinical testing of DENVax has been initiated.
Related Topics
Life Sciences
Immunology and Microbiology
Immunology
Authors
Jorge E. Osorio, Claire Y.-H. Huang, Richard M. Kinney, Dan T. Stinchcomb,